Patient-specific tumor neoantigens — Drug Target

All drugs that target Patient-specific tumor neoantigens — marketed and clinical-stage. Includes 3 drug classes acting on this target.

Drug classes

Personalized neoantigen vaccine · Therapeutic cancer vaccine · mRNA vaccine

Marketed (1)

• aMIL · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Personalized neoantigen vaccine · Oncology
  aMIL is a personalized neoantigen vaccine that trains the immune system to recognize and attack cancer cells expressing patient-specific tumor mutations.

Phase 3 pipeline (6)

• HAPREP® · National Cancer Center, Korea · Therapeutic cancer vaccine · Oncology
  HAPREP is a therapeutic cancer vaccine that primes the immune system to recognize and attack cancer cells expressing shared tumor-associated antigens.
• Begrivac® · Chiltern Pesquisa Clinica Ltda · Therapeutic cancer vaccine · Oncology
  Begrivac is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.
• mRNA-1010 · ModernaTX, Inc. · Personalized neoantigen vaccine · Oncology
  mRNA-1010 is a therapeutic cancer vaccine that encodes personalized tumor-associated neoantigens to stimulate the patient's immune system to recognize and attack cancer cells.
• IMA901 · Immatics Biotechnologies GmbH · Personalized neoantigen vaccine · Oncology
  IMA901 is a personalized neoantigen vaccine that trains the immune system to recognize and attack cancer cells expressing patient-specific tumor mutations.
• MSB0010718C · Istituto Oncologico Veneto IRCCS · Therapeutic cancer vaccine · Oncology
  MSB0010718C is a therapeutic cancer vaccine designed to activate the immune system against tumor-associated antigens.
• TAK-019 · Takeda · Therapeutic cancer vaccine · Oncology
  TAK-019 is a therapeutic vaccine designed to stimulate immune responses against cancer cells expressing specific tumor-associated antigens.

Phase 2 pipeline (1)

• BNT166a · BioNTech SE · mRNA vaccine · Oncology
  BNT166a is an mRNA vaccine designed to encode tumor-associated antigens and stimulate anti-tumor immune responses.